STERIALS

A clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate the activity of G-protein-coupled receptors (GPCRs). Utilizing the vasodilatory and anti-fibrotic properties of relaxin, the company is conducting clinical trials targeting group 2 pulmonary hypertension, as well as developing treatments for hereditary hemorrhagic telangiectasia and other conditions. Based in Delaware.